Posted by AGORACOM
at 8:37 AM on Wednesday, December 18th, 2019
Trace Analytics Inc. is a leading scalable
analytics cannabis/cannabinoid laboratory poised to meet the demands for
mandated regulatory cannabis/cannabinoid testing
WSDA contracted Trace Analytics for the purpose of doing
cannabinoid profiling for the State’s industrial hemp program to ensure
the percentages of certain cannabinoids are below Federal limits
Applied BioSciences Corp.
(OTCQB:APPB) (“Applied” or the “Company”), today announced that the
Washington State Department of Agriculture (WSDA) has extended its
contract for services with Applied’s majority owned subsidiary, Trace Analytics Inc. (“Trace”).
The WSDA contracted Trace beginning in July 2019 for the testing of
Industrial Hemp samples and percentage testing for delta
9-tetrahydrocannabidiol (THC) and delta 9-tetrahydocannabinolic acid
(THC-A) to ensure the percentages of certain cannabinoids are below
Federal limits.
“We are grateful for our relationship with the WSDA and are pleased
to continue cannabinoid profiling for the WSDA’s Industrial Hemp
program. The testing and reporting of results that we have conducted to
date have demonstrated the quality of our analytics and our dedication
to ensuring compliance with Federal limits,” stated Jason Zitzer, Chief
Operating Officer of Trace Analytics. “We provide expert consulting
services to government entities at all levels around the world and are
appreciative to WSDA to have been selected as the sole lab to conduct
their testing. This contract extension provides another opportunity
toward establishing a higher quality for cannabis and hemp testing.”
Trace Analytics Inc. is a leading cannabis science and technology
company with significant footprints in lab testing, research and
development and licensing. Trace Analytics was started by a group of
scientists who specialized in analytical chemistry, genetics and
molecular biology, focused on ensuring compliance with public safety
standards and end user safety. Trace Analytics is in the process of
expanding throughout the United States, and globally with the goal of
helping the rest of the world adopt “best practices” in cannabis and
hemp testing. The Company also provides expert consulting services to
legislators and regulators in many countries, states and municipalities
around the world.
Based on Applied BioSciences’ stated strategic corporate shift to
focus on its BioPharma division and the development and
commercialization of novel therapeutics that target the endocannabinoid
system (ECS), the Company is currently evaluating a strategic
transaction of Trace Analytics. Applied is currently in late-stage
discussions and expects to close the transaction by year end.
About Applied BioSciences Corp.
Applied BioSciences is a vertically integrated company focused on the
development and commercialization of novel, science-driven, synthetic
cannabinoid therapeutics / biopharmaceuticals that target the
endocannabinoid system to treat a wide-range of diseases across multiple
therapeutic areas. We also deliver high-quality consumer and OTC
THC-free CBD products that promote overall health and wellbeing as well
as state-of-the-art testing and analytics capabilities to our customers.
For more information, visit appliedbiocorp.com and connect with the Company on Twitter, Facebook and LinkedIn.
Posted by AGORACOM
at 4:06 PM on Tuesday, December 17th, 2019
SPONSOR: Applied BioSciences is a vertically integrated company focused on the development and commercialization of novel, science-driven, synthetic cannabinoid therapeutics / biopharmaceuticals that target the endocannabinoid system to treat a wide-range of diseases across multiple therapeutic areas Click Here for More Info
Some of us consume cannabis for its mind-altering effects, while others
seek symptom relief. But cannabis wouldn’t get us high or have some of
its therapeutic benefits if our bodies didn’t already contain a
biological system capable of interacting with its active chemical
compounds, like THC.
Our
endocannabinoid system does just that. But it isn’t there just to allow
us to enjoy the effects of our favorite strain. It serves a vital
purpose for our health and well-being because it regulates key aspects
of our biology. So, what’s it doing, and how does it work?
Homeostasis: Staying in the Goldilocks zone
To understand the human endocannabinoid system, it’s helpful to know a
little about one of the most fundamental concepts in biology:
homeostasis. And the best way to understand homeostasis is to think of
Goldilocks and the three bears.
That classic fairy tale illustrated the idea that the best outcome
often lies somewhere in the middle, between two extremes. We don’t want
things too hot or too cold, but just right.
Homeostasis is the concept that most biological systems are actively
regulated to maintain conditions within a narrow range. Our body doesn’t
want its temperature to be too hot or too cold, blood sugar levels too
high or too low, and so on. Conditions need to be just right
for our cells to maintain optimum performance, and exquisite mechanisms
have evolved to draw them back to the Goldilocks zone if they move out.
The body’s endocannabinoid system (ECS) is a vital molecular system for
helping maintain homeostasis—it helps cells stay in their Goldilocks
zone.
Key pieces of the endocannabinoid system (ECS)
Because of its crucial role in homeostasis, the ECS is widespread
throughout the animal kingdom. Its key pieces evolved a long time ago,
and the ECS can be found in all vertebrate species.
The three key components of the ECS are:
Cannabinoid receptors found on the surface of cells
Endocannabinoids, small molecules that activate cannabinoid receptors
Metabolic enzymes that break down endocannabinoids after they are used
Cannabinoid receptors
Cannabinoid receptors sit on the surface of cells and “listen†to
conditions outside the cell. They transmit information about changing
conditions to the inside of the cell, kick-starting the appropriate
cellular response.
There are two major cannabinoid receptors: CB1 and CB2. These aren’t
the only cannabinoid receptors, but they were the first ones discovered
and remain the best-studied. CB1 receptors are one of the most abundant
receptor types in the brain. These are the receptors that interact with THC to get people high.
CB2 receptors are more abundant outside of the nervous system, in
places like the immune system. However, both receptors can be found
throughout the body (Figure 1).
Figure 1: Where are CB1 and CB2 receptors located in the body?
The CB1 and CB2 receptors are key players in the endocannabinoid system
(ECS). They are located on the surface of many different types of cells
in the body. Both receptors are found throughout the body, but CB1
receptors are more abundant in the central nervous system, including on
neurons in the brain. In contrast, CB2 receptors are more abundant
outside of the nervous system, including cells of the immune system.
Endocannabinoids
Endocannabinoids are molecules that, like the plant cannabinoid THC,
bind to and activate cannabinoid receptors. However, unlike THC,
endocannabinoids are produced naturally by cells in the human body
(“endo†means “within,†as in within the body).
There are two major endocannabinoids: anandamide and 2-AG (Figure 2).
These endocannabinoids are made from fat-like molecules within cell
membranes, and are synthesized on-demand. This means that they get made
and used exactly when they’re needed, rather than packaged and stored
for later use like many other biological molecules.
Figure 2: Anandamide and 2-AG are the two major endocannabinoids.
Cannabinoids are a class of molecules characterized by their ability to
activate cannabinoid receptors like CB1 and CB2. Anandamide and 2-AG
are the two major endocannabinoids produced naturally in the body. THC
is the psychoactive plant cannabinoid produced by Cannabis. All
three of these cannabinoids can activate the CB1 and CB2 receptors,
although each one has a different potency at each receptor.
Metabolic enzymes
The third piece of the endocannabinoid triad includes the metabolic
enzymes that quickly destroy endocannabinoids once they are used. The
two big enzymes are FAAH, which breaks down anandamide, and MAGL,
which breaks down 2-AG (Figure 3). These enzymes ensure that
endocannabinoids get used when they’re needed, but not for longer than
necessary. This distinguishes endocannabinoids from many other molecular
signals in the body, such as hormones or classical neurotransmitters,
which can persist for many seconds or minutes, or get packaged and
stored for later use.
Figure 3: FAAH and MAGL are the key enzymes of the endocannabinoid system.
Enzymes are molecules that accelerate chemical reactions in the body,
often for breaking down molecules. FAAH and MAGL are key players in the
ECS because they quickly break down endocannabinoids. FAAH breaks down
anandamide, while MAGL breaks down 2-AG. These enzymes break down
endocannabinoids very quickly, but are not effective at breaking down
plant cannabinoids like THC.
The three key components of the ECS can be found within almost every
major system of the body. When something brings a cell out of its
Goldilocks zone, these three pillars of the ECS are often called upon to
bring things back, thus maintaining homeostasis. Because of its role in
helping bring things back to their physiological Goldilocks zone, the
ECS is often engaged only when and where it’s needed. Dr. Vincenzo Di Marzo, Research Director at the Institute of Biomolecular Chemistry in Italy, put it to us this way:
“With the ‘pro-homeostatic action of the ECS’ we mean
that this system of chemical signals gets temporarily activated
following deviations from cellular homeostasis. When such deviations are
non-physiological, the temporarily activated ECS attempts, in a space-
and time-selective manner, to restore the previous physiological
situation (homeostasis).â€
In other words, the ECS helps bring things back to the biological Goldilocks zone.
Below we will consider examples of how the ECS helps maintain
homeostasis in two areas: the firing of brain cells in the nervous
system, and the inflammatory response of the immune system.
Endocannabinoid regulation of brain cell firing
Brain cells (neurons) communicate by sending electrochemical signals
to each another. Each neuron must listen to its partners to decide
whether it will fire off its own signal at any given moment. However,
neurons don’t like to get too much input—there’s a Goldilocks zone. If
they get overloaded by signals, it can be toxic. That’s where
endocannabinoids come in.RelatedHow Does Cannabis Consumption Affect the Brain?
Consider a simplified scenario with one neuron listening to two
others. One of these two neurons might become overactive and send too
many signals to the neuron that’s listening. When that happens, the
neuron that’s listening will make endocannabinoids specifically where
it’s connected to the overactive neuron. Those endocannabinoids will
travel back to the “loud†neuron where they bind to CB1 receptors,
transmitting a signal that instructs it to quiet down. This brings
things back to the Goldilocks zone, maintaining homeostasis (Figure 4).
Figure 3: Endocannabinoid signals regulate how active our brain cells are.
Under normal circumstances (top-left), a given brain cell (neuron) will
get just the right amount of input from its partners—not too much, not
too little. However, some of its partners can become overactive, and
send an excessive number of signals (top-right). The neuron that’s
listening will detect this, and release endocannabinoids that tell the
other neuron to quiet down (bottom). This kind of mechanism helps
maintain homeostasis because it helps prevent neurons from sending out
too many signals.
As the example above illustrates, endocannabinoids travel backwards,
which is why they’re known as retrograde signals. Most of the time,
information flow between neurons is strictly in one direction, from
“sender†neurons that release neurotransmitter signals to “receiverâ€
neurons that listen to those signals. Endocannabinoids allow receiver
neurons to regulate how much input they’re getting, and they do this by
sending retrograde signals (endocannabinoids) back to overactive sender
neurons.
But the brain isn’t the only organ that needs to maintain
homeostasis. Every other system of the body, from the digestive to the
immune system, needs to carefully regulate how its cells are
functioning. Proper regulation is crucial for ensuring survival.
Endocannabinoid regulation of inflammation
Inflammation is a natural protective reaction the immune system has
in response to infection or physical damage. The purpose of inflammation
is to remove pathogens (germs) or damaged tissue. The inflamed area is
produced by fluid and immune cells moving into the area to do the dirty
work and return things to their Goldilocks zone.
It’s important that inflammation be limited to the location of damage
and doesn’t persist longer than needed, which can cause harm. Chronic
inflammation and auto-immune diseases are examples of the immune system
getting activated inappropriately. When that happens, the inflammatory
response lasts too long (which results in chronic inflammation) or gets
directed toward healthy cells (which is known as auto-immunity).RelatedCannabis and Arthritis
In general, endocannabinoids seem to suppress or limit the immune system’s inflammatory signals. Professor Prakash Nagarkatti,
Vice President for Research at the University of South Carolina whose
laboratory studies endocannabinoid regulation of immune responses, told
us how tweaking the ECS might be a good way to treat inflammatory
diseases.
“Most of our research demonstrates that endocannabinoids
are produced upon activation of immune cells and may help regulate the
immune response by acting as anti-inflammatory agents. Thus,
interventions that manipulate the metabolism or production of
endocannabinoids may serve as a novel treatment modality against a wide
range of inflammatory disease.â€
Consider a normal immune response triggered by a bacterial infection.
First, immune cells detect the presence of bacteria and release
pro-inflammatory molecules that tell other immune cells to come and join
the fight. Endocannabinoids get released as well (Figure 4), which also
signal to other immune cells for assistance and likely help limit the
inflammatory response so it isn’t excessive. By tightly regulating
inflammation, the immune system can destroy germs or remove damaged
tissue, and then stop. This prevents excessive inflammation, allowing
cells, and thus the body, to return to the Goldilocks zone.
Figure 4: Endocannabinoids help regulate inflammation.
Under normal conditions (top-left), cells of the immune system patrol
the body, on alert for any intruders, such as bacteria. During a
bacterial infection (top-right), immune cells detect the presence of
bacteria and then release a variety of molecules to help mount a
defensive attack (bottom). These signals include pro-inflammatory
molecules (small circles) that help recruit more immune cells to the
site of infection. Endocannabinoids (small diamonds) also get released,
and likely help regulate the magnitude and extent of this inflammatory
response.
How do plant cannabinoids like THC and CBD interact with the endocannabinoid system?
The reason that plant cannabinoids have psychoactive and medicinal
effects within the body is, in large part, because we have an
endocannabinoid system (ECS) that they can interact with. For example,
THC gets you high because it activates the CB1 receptor within the brain. Endocannabinoids like anandamide also activate CB1.
So why aren’t we constantly high?
A couple big reasons. First, THC doesn’t interact with CB1 receptors
in exactly the same fashion as the body’s natural endocannabinoids.
Second, the metabolic enzymes that quickly break down endocannabinoids
like anandamide don’t work on THC, so THC lingers around for much
longer.
It’s important to remember that molecules like cannabinoids and other
neurotransmitters rarely interact with only one receptor type; they
often interact with many. The plant-based cannabinoid CBD illustrates
this nicely, as it interacts with numerous receptor types
in the brain. So, while plant cannabinoids may activate the same
cannabinoid receptors as endocannabinoids, they will likely interact
with several other receptors and therefore have distinct effects.
CBD is also interesting because it can affect overall levels of
endocannabinoids in the brain, referred to as “endocannabinoid tone.â€
CBD inhibits the FAAH enzyme, which breaks down anandamide. Thus, CBD
can increase anandamide levels by preventing FAAH from breaking it down.
Inhibiting the FAAH enzyme has been shown to be a useful strategy for
treating anxiety disorders, and some of CBD’s anti-anxiety properties may come from its ability to inhibit this enzyme and thereby increase endocannabinoid tone.
Summary
The endocannabinoid system (ECS), comprised of cannabinoid receptors,
endocannabinoid molecules, and their metabolic enzymes, is a crucial
molecular system that the body uses to help maintain homeostasis.
Because of its vital role in making sure that cells and systems remain
in their physiological Goldilocks zone, the ECS is tightly regulated; it
gets deployed exactly when and where it’s needed. However, this doesn’t
mean that activating the ECS, through consumption of cannabis or by any
other means, will always make things just right.
Like any other complex biological system, the ECS can go awry. “If
deviation from physiological homeostasis is prolonged, due to either
external factors or chronic pathological conditions, the eCS can lose
its time- and space-selective mode of action and start affecting
inappropriate cells,†Dr. Di Marzo explained. “In these cases, the ECS,
instead of being beneficial, may actually contribute to disease
progression.â€
It’s important to remember that activating the ECS, through cannabis
consumption or by any other means, isn’t a cure-all. Like most of
biology, it’s complicated.
By understanding the biological Goldilocks principle (homeostasis),
and how the ECS illustrates this at the cellular level, we can more
deeply appreciate why we have an ECS to begin with, and how a variety of
cannabis-based therapies might actually work. The presence and critical
function of the ECS across many systems of the body, including the
nervous and immune systems, explains why such a wide variety of ailments
and disease states are responsive to cannabis-based interventions.
References
Gunduz-cinar O, Hill MN, Mcewen BS, Holmes A. Amygdala FAAH and
anandamide: mediating protection and recovery from stress. Trends
Pharmacol Sci. 2013;34(11):637-44. [PDF]
Ligresti A, De petrocellis L, Di marzo V. From Phytocannabinoids to
Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological
and Pathological Roles Through Complex Pharmacology. Physiol Rev.
2016;96(4):1593-659. [PDF]
Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M.
Cannabinoids as novel anti-inflammatory drugs. Future Med Chem.
2009;1(7):1333-49. [PDF]
Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three
plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and
delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153(2):199-215. [PDF]
Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. Science. 2002;296(5568):678-82. [PDF]
Zlebnik NE, Cheer JF. Beyond the CB1 Receptor: Is Cannabidiol the
Answer for Disorders of Motivation? Annu Rev Neurosci. 2016;39:1-17. [PDF]
Posted by AGORACOM-JC
at 3:58 PM on Tuesday, December 17th, 2019
SPONSOR:ThreeD Capital Inc. (IDK:CSE)
Led by legendary financier, Sheldon Inwentash, ThreeD is a
Canadian-based venture capital firm that only invests in best of breed
small-cap companies which are both defensible and mass scalable. More
than just lip service, Inwentash has financed many of Canada’s biggest
small-cap exits. Click Here For More Information.
Will 2020 Be The Year Of Enterprise Bitcoin?
Bitcoin is the most popular digital asset in the institutional trading world as it has the best trading options available, both spot and derivatives, proven track record with the longest history and availability of data.
This made some of the largest financial services institutions highly interested and in 2019 we saw the birth of several bitcoin products like Bakkt’s physically delivered bitcoin futures, Fidelity Digital Assets bitcoin custody solution and TD Ameritrade’s trading offerings.
Biser Dimitrov
It also the case for the large enterprises looking at blockchain as technology and wanting to innovate using easier payments over fast and secure transaction networks and processes built around smart contracts? Can they use the bitcoin blockchain as a foundation and place their middleware stack and end-user decentralized Web 3 and decentralized finance (DeFi) applications on top?
So far the majority of enterprise-focused blockchain development has
been done on permissioned and private blockchain protocols like
Hyperledger Fabric and R3’s Corda. This is mostly due to the fact that
they offer sufficient privacy, scalability and transaction finality
guarantees. Compared to them, development on top of the bitcoin
blockchain was not seriously considered until recently when in May,
Microsoft announced their permissionless, Decentralized Identifier (DID) network called ION
running exclusively on top of the bitcoin blockchain. That triggered a
shift in the sentiment that developers and enterprises should also
consider bitcoin as a potential layer for enterprise blockchain
development. For example, companies like Bitfury are already making
significant progress with enterprise-tailored blockchain offerings like blockchain as a service (BaaS) using bitcoin as a base layer.
Let’s review how bitcoin stacks up as an enterprise-ready development platform. According to a recent Ernst & Young study among decision makers across the U.S., Europe and Asia, the major reasons to consider blockchain in general are:
· Preservation of data integrity – In this area
bitcoin is the absolute winner as the most trusted and secure public
blockchain. The bitcoin blockchain is currently secured by 97
quintillion hashes per second, or EH/s. Data integrity is priority
number one for the maintainers of the bitcoin blockchain and they are
very restrictive about any new feature that can introduce security bugs
and potentially compromise the integrity of the protocol. The accuracy
and consistency of the data can be easily observed and analyzed by
simple blockchain explorers as well as by using surveillance tools like
Elliptic, Elementus and Chainalysis.
· Ability to build new revenue/business models –
Bitcoin currently has a $128 billion liquid market cap so building new
models on top of it can unlock new significant revenue channels.
Furthermore, the increased adoption of Layer 2 technology like the
Lightning Network, which operate via channels and enable cheap and fast
payments, will enable new business processes and ways to revenue.
· Increased operational efficiency – Since 2010,
when certain opcodes were taken out of the core protocol, smart
contracts were considered taboo in bitcoin. Lately, with the development
of Blockstream’s Liquid and the new RSK framework, Schnorr signatures and Taproot will make smart contracts–like executions possible via sidechains.
Posted by AGORACOM-JC
at 11:59 AM on Tuesday, December 17th, 2019
SPONSOR: CardioComm Solutions (EKG: TSX-V)
– The heartbeat of cardiovascular medicine and telemedicine. Patented
systems enable medical professionals, patients, and other healthcare
professionals, clinics, hospitals and call centres to access and manage
patient information in a secure and reliable environment.
Mobile Health (MHealth) Technologies Market Projected to Gain Significant Value
The global mHealth market should reach $46.2 billion by 2021 from $13.2 billion in 2016 at a compound annual growth rate (CAGR) of 28.6%, from 2016 to 2021.
Report Scope:
This new report on mobile health will provide a brief description of
the current status of the industry and recent developments. It presents
the changing environment, in terms of new challenges and opportunities
for app development, remote monitoring and networking medical data. The
report analyzes the market trends, leading service providers,
therapeutic markets and the most popular mHealth applications, in terms
of downloads and revenues.
Report Includes:
– A global overview of the mobile health technology market. –
Analyses of global market trends, with data from 2014 and 2015,
estimates for 2016, and projections of compound annual growth rates
(CAGRs) through 2021. – A presentation of the changing mobile health technology environment in terms of new challenges and rising opportunities. – Information regarding market trends, leading service providers, therapy markets, and the most popular mHealth applications.
– Insight into the second generation of mHealth devices, projected
regulatory patterns, and innovative devices and services to be launched
in the near future. – Company profiles of major players in the industries covered.
Report Summary
Mobile health (mHealth) is the use of mobile and wireless
technologies to support healthcare systems and achieve healthcare
objectives. Digital health solutions have the potential to improve the
quality of healthcare, to democratize medical knowledge and provide
healthcare to billions or people who have limited or no access to
services. The provision of healthcare remains high on the economic and
political agenda and continues to demand a huge share of gross domestic
product (GDP) in industrialized countries, where an aging population and
increase in the prevalence of chronic noncommunicable diseases (NCDs)
remains a challenge.
mHealth can provide better and more consistence solutions within the
global healthcare environment and will change the way services are
provided in the future. Smart devices and wearable are empowering
individuals to more effectively manage their care, raising awareness,
providing continuous monitoring and disseminating of information to the
patient and healthcare professionals; driving a more proactive,
patient-centric healthcare system.
Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
Recently launched CBD extraction facility
First extraction system capacity = 6,000 Kg per year.
CBD based products are poised to be a $20B global industry by 2022
Medical cannabis is poised to be a $100B global industry by 2025
As Smoke Clears From 2019, The US Cannabis Market Focuses On 2020
The U.S. legal cannabis market is forecast to grow to $30 billion by 2025, as state markets quickly cannibalize demand from the illicit market, thereby achieving a key objective of legalization in undercutting the unregulated activities
Through the robust growth in currently legal markets, cannabis will likewise continue to be a significant generator of new jobs (from 258,437 in 2019, to a projected 743,196 in 2025 – an increase of 188%), and of tax revenues for the federal and state goverments ($1.41 billion in 2019, projecting to $4.06 billion in 2025)
While 2019 was a year marked by turbulence
and reconsidered expectations in the legal cannabis industry,
significant opportunities for growth and prosperity nevertheless await
in 2020.
Despite strong consumer demand, challenges in operationalizing key
markets – including Canada and California – coupled with slow progress
toward U.S. federal legalization (among other reasons) have resulted in a
slowdown in cannabis investments and dramatic contraction in value of
the largest companies.Though the mysterious vaping crisis
of EVALI (i.e., “e-cigarette or vaping, product use associated lung
injuries”) threw a virtual wrench into a segment which had been
projected to account for 29% of U.S. legal cannabis sales and $4.9
billion in 2019, other categories have seen strong sustained growth amid
strong consumer demand.
The U.S. legal cannabis market is forecast to grow to $30 billion by
2025, as state markets quickly cannibalize demand from the illicit
market, thereby achieving a key objective of legalization in
undercutting the unregulated activities. Through the robust growth in
currently legal markets, cannabis will likewise continue to be a
significant generator of new jobs (from 258,437 in 2019, to a projected
743,196 in 2025 – an increase of 188%), and of tax revenues for the
federal and state goverments ($1.41 billion in 2019, projecting to $4.06
billion in 2025).
Given the growth seen in Colorado’s successful program, a prosperous market is achievable if deftly managed, and critical growing pains are avoided.
However, it takes years for the market’s economics to stabilize, a
period during which efficiency, scale, and competition all increase
dramatically. Even as Colorado’s legal market nears saturation,
wholesale prices (which have already fallen by half) in the Rocky
Mountain State are expected to continue to fall, driving further
consolidation as less efficient and undifferentiated producers are
displaced by high-performing operators.
Meantime, markets are opening in Illinois and Michigan, and Florida seems headed
for an adult-use referendum in the nation’s third-most populous state,
which approved medical use with 71% in favor in 2016. Almost all
Americans now live in a market which has expanded to include access to
either CBD, medical, or full adult-use purchases. And with more than a
dozen other states likely to further expand legal cannabis access within
the next two or three years, the delays in federal regulatory reform
appear to be doing little to slow the public’s rising enthusiasm for
legalization.
Innovation is driving development of new products. A far-flung range of cannabis-related technologies
are emerging to attract new demographic groups and new opportunities
through everything from Big Data business analytics to compliance
testing, new extraction technologies, and the rise of smart consumption
devices.
U.S. hemp saw a 459% increase in cultivation acreage from 2018 to
2019. Passage of the 2018 U.S. Farm Bill catalyzed the dramatic growth,
though lack of the industry’s processing capacity coupled with
supply-chain challenges to leave some early producers struggling to get
harvests and products to market.
Here too, innovation and commercialization will play a transformative
role, activating new applications that are in development, from
bioplastics to construction materials. As the U.S. hemp industry matures,
it will transition from being a seed, textile, and industrial product
importer to a global exporter. Though the U.S. had lagged behind
countries like Canada and France with hemp legislation, the 2018 Farm
Bill cleared the way for the U.S. industry to accelerate and establish
itself as a global exporting powerhouse led by hemp-derived CBD.
While the U.S. federal government through the Food and Drug
Administration (FDA) and the U.S. Agriculture Department (USDA) offers
more confusion than clarity about the legality of CBD products and use, domestic and international demand keeps expanding apace.
While the FDA promises guidance to be forthcoming, it is likelier that confusion will confound
consumers for the foreseeable future, throughout 2020 and beyond until
the long-term research studies which federal prohibition prevented for
decades can finally be performed.
Heading into the new year, the convergent forces which characterized
2019’s turbulence are not yet resolved. However, as the irrational
exuberance that has fueled much of the speculative investments in
cannabis has been displaced by a more clear-eyed, long-term strategic
approach, the companies that weather the storm will be keenly positioned
to capitalize on the significant growth opportunities which legal
cannabis will present globally in 2020.
Click Here to see 10 intriguing cannabis statistics from 2019
Posted by AGORACOM-JC
at 7:30 PM on Sunday, December 15th, 2019
This decade began with incredible hope for graphene as the miracle material that would change everything.
By 2015, hope gave way to indifference as graphene failed to live up to the smallest of expectations.
With the next decade just 15 days away, ZEN Graphene Solutions has reignited the great graphene hope with a string of great successes in 2019 that put commercialization within sight.
If you walked away from graphene years ago, you now owe it to yourself to watch this interview with ZEN CEO Francis Dube and find out why 2020 could mark the start of the graphene decade.
Posted by AGORACOM-JC
at 3:15 PM on Friday, December 13th, 2019
SPONSOR:ThreeD Capital Inc. (IDK:CSE)
Led by legendary financier, Sheldon Inwentash, ThreeD is a
Canadian-based venture capital firm that only invests in best of breed
small-cap companies which are both defensible and mass scalable. More
than just lip service, Inwentash has financed many of Canada’s biggest
small-cap exits. Click Here For More Information.
Dutch Bank ING Reportedly Working on Crypto Custody Tech
Netherlands-based banking multinational ING is developing technology for the custody of crypto assets, according to Reuters.
By: Daniel Palmer
The news agency said in a report on Wednesday that sources “familiar with the matter” indicated the ultimate aim of the initiative is to provide secure crypto storage facilities for the bank’s customers.
The tech, though still in the early stages, is apparently being built by a team based in Amsterdam.
Responding to Reuters in a statement, ING said it “sees increasing
opportunities with regard to digital assets on both asset backed and
native security tokens,†and is taking a particular focus on developing
blockchain technology to open up the sector for clients.
ING is already involved in a number of blockchain initiatives, with its dedicated development team saying in April that it’s working on privacy technology called “bulletproofs” to potentially conceal client data.
If ING now moves into custodianship of crypto assets, it will be one
of very few traditional finance institutions to have done so.
Fidelity’s digital assets arm launched custody services earlier this year, as did Bakkt,
the bitcoin derivatives subsidiary of Intercontinental Exchange. A plan
by Japanese bank Nomura to offer institutional-grade custody for
digital assets was delayed till 2020 in spring.
Otherwise, only a few smaller banks such as Julius Baer and Arab Bank’s Swiss arm have moved to offer the service in a bid to attract clients.
Posted by AGORACOM-JC
at 8:07 AM on Friday, December 13th, 2019
Announced that its wholly-owned subsidiary, Empower Healthcare Assets Inc., has issued a convertible promissory note in the principal amount of CAD$250,000 to Heritage
Under the terms of the LOI, Empower and Heritage will each hold a 50% ownership interest in the JV entity.
Heritage, via its wholly owned subsidiary, Purefarma Solutions Inc. will install extraction units and related downstream extraction equipment inside Empower’s existing 5,000 sq. ft. licenced hemp processing facility in Sandy, OR.
HERITAGE CANNABIS HOLDINGS CORP. (CSE:CANN) (“Heritage”) provides $250,000 of funding to support the development of the previously announced Empower – Heritage Extraction Center Joint Venture (the “JV”) in Sandy, OR.
VANCOUVER, BC / December 13, 2019 / EMPOWER CLINICS INC. (CSE:CBDT)(OTC:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company“), a vertically integrated and growth-oriented CBD life sciences company, is pleased to announce that its wholly-owned subsidiary, Empower Healthcare Assets Inc., has issued a convertible promissory note (the “Note“) in the principal amount of CAD$250,000 to Heritage, pursuant to an initial first funding under the letter of intent (the “LOI“) previously announced by the Company on September 17, 2019.
Under the terms of the LOI, Empower and Heritage will each hold a 50% ownership interest in the JV entity (“NewCo“). Heritage, via its wholly owned subsidiary, Purefarma Solutions Inc. (“Purefarma“),
will install extraction units and related downstream extraction
equipment inside Empower’s existing 5,000 sq. ft. licenced hemp
processing facility in Sandy, OR. In addition, Purefarma will train and
supervise staff on the proprietary methods of extraction and oil
production that it utilizes in Canada. The JV will be equally funded by
both companies, with Heritage investing an initial $500,000 for start-up
funds, as the build-out completes and the JV secures high quality hemp
supply from local growers.
“Securing the initial advance from Heritage demonstrates the
confidence both companies have in being able to finalize a definitive
agreement for the formation of the JV and commence full operations at
the Sandy, OR facility,” said Steven McAuley, Empower’s Chairman and
CEO. “Receiving the advance allows us to place purchase orders for
equipment and complete 2020 state licensing requirements to begin
product production, which is expected to be followed soon after by the
set up of the hemp-derived CBD extraction equipment.”
“We at Heritage continue to be excited and optimistic about our
potential with the large U.S. markets. Having a distribution partner
like Empower and a licenced facility together are expected to allow us
to accelerate our path to new revenue and support the order pipeline we
are building,” said Clint Sharples, CEO of Heritage.
The Note bears interest at the rate of 2.0% per annum and will mature
no later than December 31, 2021. The Note contains an optional
conversion provision for Heritage to surrender the Note in exchange for
shares in the capital of Empower. The number of Empower shares to be
issued to Heritage will be based on the value of the shares at the close
of business the day before this Note is surrendered to the Company,
subject to a minimum conversion price of $â—, being the closing price of
the shares on the Canadian Securities Exchange (the “CSE“) on December â—, 2019.
A further optional conversion provision provides that, on or after
the date when a definitive agreement is executed and delivered by the
parties in connection with the JV, Heritage may surrender the Note to
the Company in exchange for an equity interest in Newco equal to
Heritage’s pro-rata cash investment in NewCo made pursuant to the Note,
provided however, that the Company shall have 60 days to match
Heritage’s contribution to NewCo, such that if the Company or an
affiliate invests an amount equal to Heritage’s investment, the equity
ownership in NewCo will be held equally by Heritage and the Company.
Upon conversion, all amounts advanced under the Note shall be deemed to
be an equity advance to NewCo for purposes of the JV.
The proceeds of the Note shall be used solely in connection with the
JV and the incorporation of Newco. The proceeds shall not be used to
repay the outstanding balance under any existing or future bank or
credit facility or similar arrangement, including any scheduled payments
of principal and interest.
The Note and any Empower shares issued thereunder will be subject to a
statutory hold period of four months and one day from the date of the
issuance of the Note under applicable Canadian securities laws, as well
as resale restrictions under applicable United States securities laws.
The issuance of the Note and any Empower shares are subject to the
approval of the CSE. Neither the Note nor any of the Empower shares that
may be issuable thereunder will be registered under the United States Securities Act of 1933,
as amended, and none may be offered or sold in the United States absent
registration or an applicable exemption from the registration
requirements. This press release shall not constitute an offer to sell
or the solicitation of an offer to buy any securities of the Company,
nor shall there be any sale of the securities in any jurisdiction in
which such offer, solicitation or sale would be unlawful.
ABOUT EMPOWER
Empower is a leading owner/operator of a network of physician-staffed
clinics focused on helping patients improve and protect their health
through innovative uses of medical cannabis. It is expected that
Empower’s proprietary product line “Sollievo” will offer patients a
variety of delivery methods of doctor recommended cannabidiol (CBD)
based product options in its clinics, online and at major retailers.
With over 165,000 patients, an expanding clinic footprint, a focus on
new technologies, including tele-medicine, and an expanded product
development strategy, Empower is undertaking new growth initiatives to
be positioned as a vertically integrated, diverse, market-leading
service provider for complex patient requirements in 2019 and beyond.
ABOUT HERITAGE CANNABIS HOLDINGS CORP.
The Company is a vertically integrated cannabis provider that
currently has two Health Canada approved licenced producers, through its
subsidiaries Voyage Cannabis Corp. and CannaCure Corp. both regulated
under the Cannabis Act Regulations. Working under these two licences,
Heritage has two additional subsidiaries, Purefarma Solutions, which
provides extraction services, and BriteLife Sciences that is focused on
cannabis based medical solutions. Heritage as the parent Company, is
focused on providing resources for its subsidiaries to advance their
products or services to compete both domestically and internationally.
ON BEHALF OF THE BOARD OF DIRECTORS:
Steven McAuley Chief Executive Officer
CONTACTS:
Investors: Steve Low Boom Capital Markets [email protected] 647-620-5101
For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI
DISCLAIMER FOR FORWARD-LOOKING STATEMENTS
This news release contains certain “forward-looking statements”
or “forward-looking information” (collectively “forward looking
statements”) within the meaning of applicable Canadian securities laws.
All statements, other than statements of historical fact, are
forward-looking statements and are based on expectations, estimates and
projections as at the date of this news release. Forward-looking statements
can frequently be identified by words such as “plans”, “continues”,
“expects”, “projects”, “intends”, “believes”, “anticipates”,
“estimates”, “may”, “will”, “potential”, “proposed” and other similar
words, or information that certain events or conditions “may” or “will”
occur. Forward-looking statements in this news release include
statements regarding: the proposed JV; the Company’s intention to open a
hemp-based CBD extraction facility; the expected use of proceeds of the
Note; the expected benefits to the Company and its shareholders as a
result of the proposed JV. Such statements are only projections, are
based on assumptions known to management at this time, and are subject
to risks and uncertainties that may cause actual results, performance or
developments to differ materially from those contained in the
forward-looking statements, including that: Heritage and Empower may be
unable to agree on terms of a definitive agreement with respect to the
JV; that the Company may not open a hemp-based CBD extraction facility;
that legislative changes may have an adverse effect on the Company’s
business and product development; that the Company may not be able to
obtain adequate financing to pursue its business plan; general business,
economic, competitive, political and social uncertainties; failure to
obtain any necessary approvals in connection with the proposed JV or
extraction facility; and other factors beyond the Company’s control. No
assurance can be given that any of the events anticipated by the
forward-looking statements will occur or, if they do occur, what
benefits the Company will obtain from them. Readers are cautioned not to
place undue reliance on the forward-looking statements in this release,
which are qualified in their entirety by these cautionary statements.
The Company is under no obligation, and expressly disclaims any
intention or obligation, to update or revise any forward-looking
statements in this release, whether as a result of new information,
future events or otherwise, except as expressly required by applicable
securities laws.
Tags: CSE, Hemp, Marijuana, stocks, tsx, tsx-v, weed Posted in All Recent Posts, Empower Clinics Inc. | Comments Off on Heritage Cannabis Provides Initial $250,000 Financing to Empower Clinics $CBDT.ca for Joint Venture Extraction Facility $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca $FAF.ca
Posted by AGORACOM
at 4:19 PM on Thursday, December 12th, 2019
SPONSOR: Labrador Gold – Two successful gold explorers lead the way in the Labrador gold rush targeting the under-explored gold potential of the province. Exploration has already outlined district scale gold on two projects, including a 40km strike length of the Florence Lake greenstone belt, one of two greenstone belts covered by the Hopedale Project. Click Here for More Info
Completed gold acquisitions have reached about $33 billion so far in 2019, the highest since 2011
A torrent of deal-making among gold producers that’s pushed M&A in the sector to an eight-year high is seen spilling over into the wider mining industry — if there’s a rally in global growth.
Pending and completed gold acquisitions have reached about
$33 billion so far in 2019, the highest since 2011, according to data complied
by Bloomberg. That’s as deals among all mining companies have declined about
29% from last year to $60-billion, the data show.
A revival in the economic outlook, with higher interest
rates and inflation, would prompt other metals producers to rethink their
current strategy of cutting debt and lifting shareholder returns — and focus
again on pursuing growth, according to Christopher LaFemina, a New
York-based analyst at Jefferies.
“Until now, the market has rewarded companies for austerityâ€
amid a chase for yield, LaFemina said in a phone interview. “We will see a
significant acceleration of M&A activity when global growth recovers.â€
In recent times, the biggest miners, including Rio Tinto and
BHP, have made only some small investments in undeveloped projects and
authorized new spending on expansions at existing operations.
Larger-scale M&A could be an option for Rio next year,
UBS Group analysts, including Glyn Lawcock, said in a report this month.
“Will 2020 see the shackles come off? Growth in the portfolio is limited,†they
said.
Rio has a “watching brief for attractive M&A
opportunities,†though intends to remain “absolutely disciplined,†CEO Jean-Sebastien
Jacques told investors at an October seminar. The company has said its
ventures team is evaluating opportunities in battery materials, including in
nickel. There would be “plenty of logic†for Rio in adding copper producer
First Quantum Minerals, according to Barclays.
BHP is also seeking to add oil, copper and nickel, and could
consider deals that offer an early entry into high-quality resource bases,
particularly before the value of a project is fully understood, CFO Peter
Beaven said in May.
Still, large companies and their investors continue to be
chastened by past failed deals, according to Paul Mitchell, EY’s global mining
and metals leader, and they remain cautious after a multi-year effort to repair
balance sheets in the wake of the 2015 price collapse.
Sectors such as base metals have fewer opportunities for
consolidation than precious metals, and a price downturn hasn’t yet forced
companies into distress, according to David Harquail, chief executive officer
at Franco-Nevada Corp., a mine streaming and royalty company.
Since January’s $10-billion gold mega-merger between then
Newmont Mining and Goldcorp, companies in the sector including Newcrest Mining
have added individual mines, while Kirkland Lake Gold and Zijin Mining Group
acquired smaller rivals. Barrick Gold and a partner on Tuesday agreed to a $430
million deal to sell a 90% stake in a project in Senegal to with Teranga Gold.
Gold’s rally means there’s been “a slightly improved
environment to be able to finally do transactions,†Harquail said. There’s a
prospect of further activity among gold producers into next year, with
investors ready to back proposals that reduce overheads and combine assets, he
said.
“I want to see smart consolidation, not the same thing that
we’ve seen in the past†among gold producers, said Joe Foster, a New York-based
portfolio manager at Van Eck. “There’s value to be created by consolidating
some of these single-asset companies.â€
Posted by AGORACOM
at 3:06 PM on Thursday, December 12th, 2019
Ken Konkin Discusses the Goldstorm Deposit at Treaty Creek (including recent outstanding drill results like 0.725 g/t over 838.5m), it’s Potential, and 2020 Development Plans
American
Creek is a Canadian junior mineral exploration company with a strong
portfolio of gold and silver properties in British Columbia.
Three
of those properties are located in the prolific “Golden Triangleâ€; the
Treaty Creek and Electrum joint venture projects with Tudor Gold/Walter
Storm as well as the 100% owned past producing Dunwell Mine.
The
Treaty Creek Project is a Joint Venture with Tudor Gold owning 60% and
acting as operator. American Creek and Teuton Resources each have 20%
interests in the project. American Creek and Teuton are both fully
carried until such time as a Production Notice is issued, at which time
they are required to contribute their respective 20% share of
development costs. Until such time, Tudor is required to fund all
exploration and development costs while both American Creek and Teuton
have “free ridesâ€.
The Corporation also holds the Gold Hill, Austruck-Bonanza, Ample Goldmax, Silver Side, and Glitter King properties located in other prospective areas of the province.
For further information please contact Kelvin Burton at: Phone: 403 752-4040 or Email: [email protected]. Information relating to the Corporation is available on its website at www.americancreek.com.
Hub on Agoracom FULL DISCLOSURE: American Creek is an advertising client of AGORA Internet Relations Corp.